**CURRICULUM VITAE**

Prof Francesca Patriarca

Tax code PTRFNC64M49L483Y

EDUCATION ANS SCHOLARSHIP

* Medicine and Surgery degree obtained “cum Laude”at the Catholic University of Rome in July 1989.
* Medical License N° 3582 January 10, 1990
* Specialization in Medical Oncology with 70/70 obtained at the University of Padua in 1993.
* Specialization in Haematology “cum laude”at the University of Udine in 1998.

ACADEMIC POSITION

* Researcher MED 15/Blood diseases at Udine University 2007-2020
* Associate Professor MED 15/Blood diseases at Udine University since 2020 October

MEDICAL RELEVANT WORK EXPERIENCE

* Assistant at the Internal Medicine Department of the General Hospital of Udine between 1992 and 1995.
* Assistant at the Haematological Department and Bone Marrow Transplantation Unit , University Hospital of Udine since 1996.
* Coordinator of Transplant Unit ‘ Carlo Melzi’ , at Clinica Ematologica, Azienda Sanitaria -Universitaria , p.zale S. Maria della Misericordia 10, 33100 Udine, Italy, since 2004
* High specialization assignment entitled ”Management of stem cell transplantation” since 2010

PROFESSIONAL MEMBERSHIP

* Member of the Board of the Working Party Multiple Myeloma of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) since 2010, with the role of coordinating the scientific meetings in the area of Triveneto (since 2010) and of coordinating the Transplant Committee (since 2017)
* Member of the Board of Gruppo Italiano Trapianto di Midollo Osseo (GITMO) since 2015, Allogeneic Transplant Activity Coordinator between 2015 and 2019
* Member of the Board of Società Italiana di Ematologia (SIE) since 2017

EXPERIENCE ABROAD

• Course " Training course on lymphomas" in Vienna, April 1994 , organized by the dall’European School of Oncology

• Course " Clinical Exchange Program" at MD Anderson Cancer Center at Texas University , USA (November 1999).

• "Visitor Physician" at the Department of Blood and Marrow transplantation, MD Anderson Cancer Center, University of Texas, involved in the in-patient and out-patient clinical activity, with specific interest in reduced intensity and non mieloablative conditioning of lymphomas and multiple (May-June 2000).

• Course " Decision Making in haematological malignancies: the Hammersmith approach" at the Department of Bone Marrow Transplantation of the Hammersmith Hospital, University of London (October 2001).

• Course: “Advanced course on multiple myeloma” at the John Hopkins University of Baltimore (USA) (October 2010)

TEACHING ACTIVITY

• Since 2007 Assistant Professor and Coordinator at the Nursing degree , Oncology Area, at the University of Udine

• Since 2007 Assistant Professor of the Medicine and Surgery degree , Hematology Course and assistant professor of the Specialization in Hematology, at the University of Udine

• Member of the Organizer Committee and Professor of the II Level Master entitled “ Stem cell Transplant and Cellular Therapies” in the years 2008-9 and 2010-11 promoted by the Specialization Schools of Firenze and Udine

• Professor of the II level Master entitled : Diagnosis and Therapy of lymphomas”, years 2013-4 and 2015-6

EDITORIAL COLLABORATION

• Reviewer of the following scientific journals: Bone Marrow Transplantation, Biology Blood and Marrow Transplantation, Haematologica, Hematological Oncology; reviewer of abstracts for the meeting of the Italian Society of Hematology and of Italian Society of Experimental Hematology

* Guidelines on “Multiple Myeloma “ of the Italian Society of Medical Oncology since 2012

• “Practical manual for the management of Multiple Myeloma “ Publishing house Edra , 2015 and 2017

• “ Emesis and treatment of haematological tumours “Publishing house Pensiero scientifico ,2012, 2015 and 2018 .

• web site GITMOTWITTING www. Gitmotwitting.it , that is a web site for the diffusion and discussion of recent scientific publications regarding hematopoietic stem cell transplantation , promoted by the Society Gruppo Italiano Trapianti di Midollo osseo (GITMO), active since May 2016. Editorial curator of the section: Haploidentical transplant and Cellular Therapy Section

STUDIES COORDINATION

* Principal Investigator of the Italian multicentre study sponsored by FONESA : “Prospective, phase II study to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who have relapsed after previous high-dose therapy” (.MM-SDX-105-01 EUDRACT Number 2014-000130-37)
* Principal Investigator of the multicentre Italian study sponsored by GITMO : “Prospective, phase II randomized study to evaluate the efficacy and the safety of the reduced-intensity conditioning regimen fludarabine-busulfan in comparison to fludarabine-thiotepa as preparative regimen before the allogeneic transplant for myelofibrosis( GITMO – MF 2010,EUDRACT Number 2010-022052-23).
* Principal Investigator of the Italian multicentre observational study sponsored by GITMO: “Adoptive immunotherapy with donor lymphocyte infusion in acute leukemia: the Italian experience”, approved by the Etical Committee of Udine, EUDRACT number ongoing
* Participation to several national and international interventional prospective studies in the field of multiple myeloma and allogeneic stem cell transplantation

ORAL PRESENTATIONS AT NATIONAL AND INTERNATIONAL CONGRESSES

* XXXIII Italian Society of Hematology (SIE), Verona, 1991;
* V Italian Society of Experimental Hematology (SIES), , Siena, 1998,
* 41° Italian Society of Hematology (SIE), Bologna October 2007 (oral presentation selected for general session)
* New drugs and hematopoietic stem cell transplantation in oncohematological diseases of the elderly, Roma October 2009,
* American Society of Hematology, New Orleans December 2009;
* European Bone Marrow Transplantation Meeting , Vienna March 2010.,
* 44° Italian Society of Hematology (SIE), Verona October 2013 (Educational Section);
* European Bone Marrow Transplantation Meeting , Istambul March 2015;
* 15° International Myeloma Workshop, Meet the expert session. Roma, 23-26/9/2015
* 45° Italian Society of Hematology, Firenze: 4-7October 4-7, 2015, 2 oral presentations, 1 of these was selected for the general section
* 46° Italian Society of Hematology, Roma: October15-18, 2017
* European Bone Marrow Transplantation Meeting , Lisbon March 18-21 March 2018
* European Bone Marrow Transplantation Meeting , March 18-21 March 2018

PUBLICATIONS

190 full papers were published in international scientific journals with peer review system, with a global H-index of 50. The publications of the 2016-2017 period are the following:

1. Ladetto M, Ferrero S, Drandi D, Festuccia M, **Patriarca F**, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M, Bruno B.[Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma.](http://www.ncbi.nlm.nih.gov/pubmed/26437784) Leukemia. (2016) **30,** 1211–1214;.
2. Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, **Patriarca F,** Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A.[Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.](http://www.ncbi.nlm.nih.gov/pubmed/26429297) Lancet Oncol. Lancet Oncol 2015; 16: 1525–36
3. [Zamagni E](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zamagni%20E%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)1, [Nanni C](http://www.ncbi.nlm.nih.gov/pubmed/?term=Nanni%20C%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)2, [Gay F](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gay%20F%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)3, [Pezzi A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Pezzi%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)1, [**Patriarca F**](http://www.ncbi.nlm.nih.gov/pubmed/?term=Patriarca%20F%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)**4**, [Bellò M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Bell%C3%B2%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)5, [Rambaldi I](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rambaldi%20I%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)2, [Tacchetti P](http://www.ncbi.nlm.nih.gov/pubmed/?term=Tacchetti%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)1, [Hillengass J](http://www.ncbi.nlm.nih.gov/pubmed/?term=Hillengass%20J%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)6, [Gamberi B](http://www.ncbi.nlm.nih.gov/pubmed/?term=Gamberi%20B%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)7, [Pantani L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Pantani%20L%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)1, [Magarotto V](http://www.ncbi.nlm.nih.gov/pubmed/?term=Magarotto%20V%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)3, [Versari A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Versari%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)8, [Offidani M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Offidani%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)9, [Zannetti B](http://www.ncbi.nlm.nih.gov/pubmed/?term=Zannetti%20B%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)1, [Carobolante F](http://www.ncbi.nlm.nih.gov/pubmed/?term=Carobolante%20F%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)4, [Balma M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Balma%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)5, [Musto P](http://www.ncbi.nlm.nih.gov/pubmed/?term=Musto%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)10, [Rensi M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rensi%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)11, [Mancuso K](http://www.ncbi.nlm.nih.gov/pubmed/?term=Mancuso%20K%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)1, [Dimitrakopoulou-Strauss A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Dimitrakopoulou-Strauss%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)12, [Chauviè S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Chauvi%C3%A8%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)13, [Rocchi S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rocchi%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)1, [Fard N](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fard%20N%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)14, [Marzocchi G](http://www.ncbi.nlm.nih.gov/pubmed/?term=Marzocchi%20G%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)1, [Storto G](http://www.ncbi.nlm.nih.gov/pubmed/?term=Storto%20G%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)15, [Ghedini P](http://www.ncbi.nlm.nih.gov/pubmed/?term=Ghedini%20P%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)2, [Palumbo A](http://www.ncbi.nlm.nih.gov/pubmed/?term=Palumbo%20A%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)3, [Fanti S](http://www.ncbi.nlm.nih.gov/pubmed/?term=Fanti%20S%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)2, [Cavo M](http://www.ncbi.nlm.nih.gov/pubmed/?term=Cavo%20M%5BAuthor%5D&cauthor=true&cauthor_uid=26490489)18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease.[Leukemia.](http://www.ncbi.nlm.nih.gov/pubmed/26490489) 2016 Feb;30(2):417-22.
4. Nanni C, Zamagni E, Versari A, Chauvie S, Bianchi A, Rensi M, Bellò M, Rambaldi I, Gallamini A, **Patriarca F**, Gay F, Gamberi B, **Cavo** M, Fanti S. [Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe).](http://www.ncbi.nlm.nih.gov/pubmed/26475305)Eur J Nucl Med Mol Imaging. 2016 Mar;43(3):414-21
5. Mian M, Tinelli M, DE March E, Turri G, Meneghini V, Pescosta N, Berno T, Marabese A, Mondello P, Patriarca F, Pizzolo G, Semenzato G, Cortelazzo S, Zambello R.[Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?](http://www.ncbi.nlm.nih.gov/pubmed/26976998)Anticancer Res. 2016 Mar;36(3):1059-65.
6. Kröger N, Solano C, Wolschke C, Bandini G, **Patriarca F**, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F.[Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease.](http://www.ncbi.nlm.nih.gov/pubmed/26735993)N Engl J Med. 2016 Jan 7;374(1):43-53.
7. Magarotto V, Bringhen S, Offidani M, Benevolo G, **Patriarca F**, Mina R, Falcone AP, De Paoli L, Pietrantuono G, Gentili S, Musolino C, Giuliani N, Bernardini A, Conticello C, Pulini S, Ciccone G, Maisnar V, Ruggeri M, Zambello R, Guglielmelli T, Ledda A, Liberati AM, Montefusco V, Hajek R, Boccadoro M, Palumbo A.[Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma.](http://www.ncbi.nlm.nih.gov/pubmed/26729895)Blood. 2016 Mar 3;127(9):1102-8.
8. Gay F, Oliva S, Petrucci MT, Conticello C, Catalano L, Corradini P, Siniscalchi A, Magarotto V, Pour L, Carella A, Malfitano A, Petrò D, Evangelista A, Spada S, Pescosta N, Omedè P, Campbell P, Liberati AM, Offidani M, Ria R, Pulini S, **Patriarca F**, Hajek R, Spencer A, Boccadoro M, Palumbo A.[Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.](http://www.ncbi.nlm.nih.gov/pubmed/26596670) Lancet Oncol. 2015 Dec;16(16):1617-29
9. Terragna C, Remondini D, Martello M, Zamagni E, Pantani L, **Patriarca F**, Pezzi A, Levi G, Offidani M, Proserpio I, De Sabbata G, Tacchetti P, Cangialosi C, Ciambelli F, Viganò CV, Dico FA, Santacroce B, Borsi E, Brioli A, Marzocchi G, Castellani G, Martinelli G, Palumbo A, Cavo M.[The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).](http://www.ncbi.nlm.nih.gov/pubmed/26575327)Oncotarget. 2016 Mar 1;7(9):9666-79
10. Antonio Palumbo, Sara Bringhen, Alessandra Larocca, Davide Rossi, Francesco Di Raimondo,Valeria Magarotto, **Francesca Patriarca**, Anna Levi, Giulia Benevolo, Iolanda Donatella Vincelli,Mariella Grasso, Luca Franceschini, Daniela Gottardi, Renato Zambello, Vittorio Montefusco,Antonietta Pia Falcone, Paola Omede´, Roberto Marasca, Fortunato Morabito, Roberto Mina,Tommasina Guglielmelli, Chiara Nozzoli, Roberto Passera, Gianluca Gaidano, Massimo Offidani, Roberto Ria, *Maria Teresa Petrucci, Pellegrino Musto, Mario Boccadoro, and Michele Cavo.*. Bortezomib-Melphalan-Prednisone-Thalidomide Followedby Maintenance With Bortezomib-Thalidomide ComparedWith Bortezomib-Melphalan-Prednisone for InitialTreatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. J Clin Onc 2014;32(7):634-644
11. Malagola M, Cancelli V, Skert C, Leali PF, Ferrari E, Tiburzi A, Sala ML, Donnini I, Chiusolo P, Mussetti A, Battista M, Turra A, Cattina F, Rambaldi B, Schieppati F, Polverelli N, Bernardi S, Perucca S, Marini M, Laszlo D, Savignano C, **Patriarca F**, Corradini P, Piccirillo N, Sica S, Bosi A, Russo D.[Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo.](https://www.ncbi.nlm.nih.gov/pubmed/27861297)Transplantation. 2016 Dec;100(12):e147-e155.
12. **Patriarca F**, Cigana C, Dozzo M, Lazzarotto D, Geromin A, Isola M, Battista ML, Medeot M, Cerno M, Sperotto A, Candoni A, Crapis M, Sartor A, Scarparo C, Bassetti M, Fanin R.[Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell Transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/27826061)Biol Blood Marrow Transplant. 2017; 23 (2):333-339.
13. Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, Drandi D, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, **Patriarca F**, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, Omedè P.[Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.](https://www.ncbi.nlm.nih.gov/pubmed/27779105)Oncotarget. 2017; 24 (8):5924-5935

# Dodero A, Patriarca F, Milone G, Sarina B, Miceli R, Iori A, Barretta F, Terruzzi E, Mussetti A, Pini M, Bosi A, Dominietto A, Cascavilla N, Onida F, Narni F, Farina L, Rambaldi A, Corradini P.Allogeneic Stem Cell Transplantation for Relapsed/Refractory B-Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial Including Rituximab in the Reduced Intensity Conditioning Regimen. Biol Blood Marrow Transpantation 2017; 23 (7): 1102-1109.

1. Todisco E, Ciceri F, Boschini C, Giglio F, Bacigalupo A, **Patriarca F**, Donnini I, Alessandrino EP, Arcese W, Iori AP, Marenco P, Cavattoni I, Chiusolo P, Terruzzi E, Castagna L, Santoro A, Bosi A, Oldani E, Bruno B, Bonifazi F, Rambaldi A. [Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).](https://www.ncbi.nlm.nih.gov/pubmed/28067875) Bone Marrow Transplant. 2017; 52 (7):955-961.
2. Candoni A, De Marchi F, Zanini F, Zannier ME, Simeone E, Toffoletti E, Chiarvesio A, Cerno M, Filì C, **Patriarca F**, Fanin R. [Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.](https://www.ncbi.nlm.nih.gov/pubmed/28159598) Exp Hematol. 2017 May;49:25-33.
3. Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, Catalano L, Evangelista A, Spada S, Campbell P, Ria R, Salvini M, Offidani M, Carella AM, Omedé P, Liberati AM, Troia R, Cafro AM, Malfitano A, Falcone AP, Caravita T, **Patriarca F**, Nagler A, Spencer A, Hajek R, Palumbo A, Boccadoro M. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017; 31(8):1727-1734.
4. **Patriarca F,** Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B.New drugs and allogeneic hematopoietic cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? Expert Opinion on Biological Therapy 2017; 17 (7):821-836.
5. Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, **Patriarca F**, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. Eur J Nucl Med Mol Imaging 2018; 45 (5):712-719.
6. Giaccone L, Mancini G, Mordini N, Gargiulo G, De Cecco V, Angelini S, Arpinati M, Baronciani D, Bozzoli V, Bramanti S, Calore E, Cavattoni IM, Cimminiello M, Colombo AA, Facchini L, Falcioni S, Faraci M, Fedele R, Guidi S, Iori AP, Marotta S, Micò MC, Milone G, Onida F, Pastore D, **Patriarca F**, Pini M, Raimondi R, Rovelli A, Santarone S, Severino A, Skert C, Stanghellini MTL, Tecchio C, Vassallo E, Chiarucci M, Bruno B, Bonifazi F, Olivieri A. ['Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).](https://www.ncbi.nlm.nih.gov/pubmed/29084200) Bone Marrow Transplant. 2018 Jan;53(1):58-63.
7. **Patriarca F**, Bruno B, Einsele H, Spina F, Giaccone L, Montefusco V, Isola M, Nozzoli C, Nozza A, Morabito F, Corradini P, Fanin R. [Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/29032267) Biol Blood Marrow Transplant. 2018 Feb;24(2):406-409. doi: 10.1016/j.bbmt.2017.10.014. Epub 2017 Oct 12.
8. Averbuch D, Tridello G, Hoek J, Mikulska M, Akan H, Yanez San Segundo L, Pabst T, Özçelik T, Klyasova G, Donnini I, Wu D, Gülbas Z, Zuckerman T, Botelho de Sousa A, Beguin Y, Xhaard A, Bachy E, Ljungman P, de la Camara R, Rascon J, Ruiz Camps I, Vitek A, **Patriarca F**, Cudillo L, Vrhovac R, Shaw PJ, Wolfs T, O'Brien T, Avni B, Silling G, Al Sabty F, Graphakos S, Sankelo M, Sengeloev H, Pillai S, Matthes S, Melanthiou F, Iacobelli S, Styczynski J, Engelhard D, Cesaro S. [Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group.](https://www.ncbi.nlm.nih.gov/pubmed/29020364) Clin Infect Dis. 2017 Nov 13;65(11):1819-1828.
9. Giaccone L, Evangelista A, **Patriarca F**, Sorasio R, Pini M, Carnevale-Schianca F, Festuccia M, Brunello L, Zallio F, Maffini E, Omedé P, Bringhen S, Mordini N, Fanin R, Ciccone G, Boccadoro M, Bruno B. [Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.](https://www.ncbi.nlm.nih.gov/pubmed/28987930) Biol Blood Marrow Transplant. 2018 Jan;24(1):189-193
10. Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, **Patriarca F**, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719
11. Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, **Patriarca F**, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M. [Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.](https://www.ncbi.nlm.nih.gov/pubmed/29479061) Leukemia. 2018 Aug;32(8):1803-1807
12. Cerrato C, Di Raimondo F, De Paoli L, Spada S, **Patriarca F**, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F. [Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.](https://www.ncbi.nlm.nih.gov/pubmed/29675792) J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366.
13. Mian M, Pescosta N, Badiali S, Cappelletto PC, Marcheselli L, Luminari S, **Patriarca F**, Zambello R, Pascarella A, Tagariello G, Marabese A, Mondello P, Billio A, Cortelazzo S. [Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.](https://www.ncbi.nlm.nih.gov/pubmed/30478966) Br J Haematol. 2019; 185 (5):944-947.
14. D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, **Patriarca F**, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F. [Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.](https://www.ncbi.nlm.nih.gov/pubmed/30447931) Crit Rev Oncol Hematol. 2018 Dec;132:9-16
15. Mina R, Petrucci MT, Corradini P, Spada S, **Patriarca F**, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S. [Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.](https://www.ncbi.nlm.nih.gov/pubmed/29910180) Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540
16. Mussetti A, De Philippis C, Carniti C, Bastos-Oreiro M, Gayoso J, Cieri N, Pennisi M, Ciceri F, Greco R, Peccatori J, **Patriarca F**, Mariotti J, Castagna L, Corradini P. [CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide.](https://www.ncbi.nlm.nih.gov/pubmed/29703966) Bone Marrow Transplant. 2018 Dec;53(12):1522-1531
17. **Patriarca F**, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MC, Bosi A, Russo D, Narni F, Messina G, Alessandrino EP, Carella AM, Milone G, Bruno B, Mammoliti S, Bruno B, Fanin R, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianti di Midollo Osseo. (GITMO). [Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.](https://www.ncbi.nlm.nih.gov/pubmed/30579966) Biol Blood Marrow Transplant. 2019; 25(5):932-940.
18. Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, **Patriarca F**, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R. [Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/30626425) J Hematol Oncol. 2019 Jan 9;12(1):4.
19. Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, **Patriarca F**, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E. Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe) Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719
20. Bringhen S, Mina R, Cafro AM, Liberati AM, Spada S, Belotti A, Gaidano G, **Patriarca F**, Troia R, Fanin R, De Paoli L, Rossi G, Lombardo A, Bertazzoni P, Palumbo A, Sonneveld P, Boccadoro M. [Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study.](https://www.ncbi.nlm.nih.gov/pubmed/29479061) Leukemia. 2018 Aug;32(8):1803-1807
21. Cerrato C, Di Raimondo F, De Paoli L, Spada S, **Patriarca F**, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F. [Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.](https://www.ncbi.nlm.nih.gov/pubmed/29675792) J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366.
22. Mian M, Pescosta N, Badiali S, Cappelletto PC, Marcheselli L, Luminari S, **Patriarca F**, Zambello R, Pascarella A, Tagariello G, Marabese A, Mondello P, Billio A, Cortelazzo S. [Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.](https://www.ncbi.nlm.nih.gov/pubmed/30478966) Br J Haematol **2019** Jun;185(5):944-947
23. D'Agostino M, De Paoli L, Conticello C, Offidani M, Ria R, Petrucci MT, Spada S, Marcatti M, Catalano L, Gilestro M, Guglielmelli T, Baldini L, Gamberi B, Rizzi R, De Sabbata G, Di Renzo N, **Patriarca F**, Pezzatti S, Siniscalchi A, Ribolla R, Palumbo A, Montefusco V, Nagler A, Boccadoro M, Gay F. [Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials.](https://www.ncbi.nlm.nih.gov/pubmed/30447931) Crit Rev Oncol Hematol. 2018 Dec;132:9-16
24. Mina R, Petrucci MT, Corradini P, Spada S, **Patriarca F**, Cerrato C, De Paoli L, Pescosta N, Ria R, Malfitano A, Musto P, Baldini L, Guglielmelli T, Gamberi B, Mannina D, Benevolo G, Zambello R, Falcone AP, Palumbo A, Nagler A, Calafiore V, Hájek R, Spencer A, Boccadoro M, Bringhen S. [Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.](https://www.ncbi.nlm.nih.gov/pubmed/29910180) Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):533-540
25. Mussetti A, De Philippis C, Carniti C, Bastos-Oreiro M, Gayoso J, Cieri N, Pennisi M, Ciceri F, Greco R, Peccatori J, **Patriarca F**, Mariotti J, Castagna L, Corradini P. [CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide.](https://www.ncbi.nlm.nih.gov/pubmed/29703966) Bone Marrow Transplant. 2018 Dec;53(12):1522-1531
26. **Patriarca F**, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MC, Bosi A, Russo D, Narni F, Messina G, Alessandrino EP, Carella AM, Milone G, Bruno B, Mammoliti S, Bruno B, Fanin R, Bonifazi F, Rambaldi A; Gruppo Italiano Trapianti di Midollo Osseo. (GITMO). [Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.](https://www.ncbi.nlm.nih.gov/pubmed/30579966) Biol Blood Marrow Transplant. 2019 May;25(5):932-940
27. Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, **Patriarca F**, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R. [Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/30626425) J Hematol Oncol. 2019 Jan 9;12(1):4.
28. Bonifazi F, Solano C, Wolschke C, Sessa M, **Patriarca F**, Zallio F, Nagler A, Selleri C, Risitano AM, Messina G, Bethge W, Herrera P, Sureda A, Carella AM, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N. [Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.](https://www.ncbi.nlm.nih.gov/pubmed/30709437) Lancet Haematol. 2019 Feb;6(2):e89-e99.
29. Girmenia C, Lazzarotto T, Bonifazi F, **Patriarca F**, Irrera G, Ciceri F, Aversa F, Citterio F, Cillo U, Cozzi E, Gringeri E, Baldanti F, Cavallo R, Clerici P, Barosi G, Grossi P. [Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies.](https://www.ncbi.nlm.nih.gov/pubmed/31310687) Clin Transplant. **2019** (10):e13666
30. Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, **Patriarca F**, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, [Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.](https://www.ncbi.nlm.nih.gov/pubmed/31221778) Haematologica. **2019** ; 105 (1):193-200.
31. Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, **Patriarca F**, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S. [First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.](https://www.ncbi.nlm.nih.gov/pubmed/31248973) Haematologica. **2019;** 105 (4):1074-1080
32. **Patriarca F**. Frontline therapy in multiple myeloma: fast start for a long game The Lancet Haematology 2019 (6) e600-e601
33. Radici V, De Marchi R, Sperotto A, Cerno M, Geromin A, Battista ML, Candoni A, Filì C, zanier ML, Lazzarotto D, Simeone E, Dubbini MV, Rabassi N, facchin G, Fanin R, **Patriarca F**. The challnage of Inotuzumab ozogamicin treatment as “bridge to transplant”in relapsed/refractory B cell-acute lymphoblastic leukemia. Hematology & Medical Oncology Journal 2019 (4): 1-4
34. Pastore D, Bruno B, Carluccio P, De Candia MS, Mammoliti S, Borghero C, Chierichini A, Pavan F, Casini M, Pini M, nassi L, Greco R, Tambaro FP, Stefanoni P, Console G, Marchesi F, Facchini L, Mussetti A, Cimminiello M, Saglio F. Vincenti D, Falcioni S, Chiusiolo P, Olivieri J, Natale A, Faraci M, Cesaro S, Marotta S, Proia A, Donnini I, Caravelli D, Zuffa E, Iori AP, Soncini E, Bozzoli V, Pisapia G, Scalone R, Prete A, Villani O, Ferarri A, Menconi M, Mancini G, Gigli F, Gargiulo G, Bruno B, **Patriarca F,** Bonifazi F. Antiemetic prophgylaxis in patients undergoing stem cell transplantation: amulticenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Annals of Hematology 2020; 99(4):867-875.
35. Montefusco V, Corso A, Galli M, Ardoino I, Pezzatti S, Carniti C, **Patriarca F**, Gherlinzoni F, Zambello R, Sammassimo S, Marcatti M, Nozza A, Crippa C, Cafro AM, Baldini L, Corradini P . Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse[.](https://www.ncbi.nlm.nih.gov/pubmed/31898319) Br J Haematology **2020**; 188(6):3900-3912.
36. Sora F, Grazia CD, Chiusolo P, Raiola AM, Bregante S, Mordini N, Olivieri A, Iori AP, **Patriarca F**, Grisariu S, Terruzzi E, Rambaldi A, Sica S, Bruno B, Angelucci E, Bacigalupo A. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study Biol Blood Marrow Transplant. **2020**; 26(4):698-703.
37. Tolomelli G, Mancuso K, Tacchetti P, **Patriarca F**, Galli M, Pantani L, Zannetti B, Motta MR, Rizzi S, Dan E, Sinigaglia B, Giudice V, Olmo A, Arpinati M, Chirumbolo G, Fanin R, Lewis RE, Paris L, Bonifazi F, Cavo M, Curti A, Lemoli RM. [The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.](https://www.ncbi.nlm.nih.gov/pubmed/31768009) Bone Marrow Transplant. 2020;55(5):946-954.
38. Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Reményi P, Wagner-Drouet EM, Hauptrock B, Dreger P, Luft T, Bethge W, Vogel W, Ciceri F, Peccatori J, Stölzel F, Schetelig J, Junghanß C, Grosse-Thie C, Michallet M, Labussiere-Wallet H, Schaefer-Eckart K, Dressler S, Grigoleit GU, Mielke S, Scheid C, Holtick U, **Patriarca F**, Medeot M, Rambaldi A, Micò MC, Niederwieser D, Franke GN, Hilgendorf I, Winkelmann NR, Russo D, Socié G, Peffault de Latour R, Holler E, Wolff D, Glass B, Casper J, Wulf G, Menzel H, Basara N, Bieniaszewska M, Stuhler G, Verbeek M, Grass S, Iori AP, Finke J, Benedetti F, Pichlmeier U, Hemmelmann C, Tribanek M, Klein A, Mylius HA, Baumgart J, Dzierzak-Mietla M, Markiewicz M. [Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.](https://www.ncbi.nlm.nih.gov/pubmed/31606445) Lancet Haematology. 2020 Jan;7(1):e28-e39.
39. Peccatori J, Mastaglio S, Giglio F, Greco R, Crocchiolo R, **Patriarca F**, Forno B, Deola S, Assanelli A, Lupo Stanghellini MT, Marcatti M, Zecca M, Cortelazzo S, Fanin R, Fagioli F, Locatelli F, Ciceri F. [Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial.](https://www.ncbi.nlm.nih.gov/pubmed/31605823) Biol Blood Marrow Transplant. 2020 Feb;26(2):316-322.
40. Lorentino F, Sacchi N, Oldani E, Miotti V, Picardi A, Gallina AM, Crivello P, Bernasconi P, Saccardi R, Farina L, Benedetti F, Cerno M, Grassi A, Bruno B, **Patriarca F,** Ciceri F, Fleischhauer K, Vago L, Bonifazi F; Gruppo Italiano per il Trapianto di Midollo Osseo, CSE e terapia cellulare (GITMO); Italian Bone Marrow Donor Registry (IBMDR). [Comparative evaluation of biological HLA-DPB1 mismatch models for survival and graft versus host disease prediction after unrelated donor hematopoietic cell transplantation.](https://www.ncbi.nlm.nih.gov/pubmed/31471374) Haematologica. 2020;105 (4):e186-e189.
41. Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringhen S, Zamagni E, **Patriarca F**, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F. [Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.](https://www.ncbi.nlm.nih.gov/pubmed/32107338) Haematologica. 2021;106 (1):291-294.
42. Zeiser R, vonBubnoff N, Butler J, Mohty M, Niederwiser D, Or R, Szer J, Wagner EM, Zuckerman T, Mahuzier B, Xu J, Wilkie C, Gandhi KK, Socie R; **REACH 2 Trial group**. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 2020; 382 (19):1800-1810.
43. Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, Versari A, Chauvie S, Gallamini A, Gamberi B, Caillot D, **Patriarca F,** Macro M, Boccadoro M, Garderet L, Barbato S, Fanti S, Perrot A, Gay F, Sonneveld P, Karlin L, Cavo M, Bodet-Milin C, Moreau P, Kraeber-Bodere F . Standardization of 18F-FDG-PET/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma. J Clin Oncol 2021; 39 (2):116-125
44. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt b, Zwegman S, Oliva S, van der Velten VHJ, Zamagni E, Palumbo GA, **Patriarca F**,…Sonneveld P. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy , and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicenter, randomized, open-label, phase 3 study: Lancet Haematol 2020; 7 (6):e456-e468.
45. Tacchetti P, Pantani L, **Patriarca F**, Petrucci MT, Zamagni E, Dozza L, Galli M, Di Raimondo F, Crippa C, Boccadoro M, Barbato S, Tosi P, Narni F, Montefusco V,…Cavo M; GIMEMA (Gruppo Italiano Malattie Ematologiche Dell’Adulto Italian Myeloma Network): Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomized phase 3 study, open-label study. Lancet Haematol 2020; 7(12): e861-e873.
46. Zamagni E, Tacchetti P, Deias P, **Patriarca F**. The role of monoclonal antibodies in smoldering and newly diagnosed transplant-elegible multiple myeloma. Pharmaceuticals (Basel) 2020; 13 (12): 451
47. Rosignoli C, Petruzzellis G, Radici V, Facchin G, Girgenti M, Stella R, Isola M, Battista M, Sperotto A, Geromin A, Cerno A, Arzese A, Deias P, Tascini C, Fanin R, **Patriarca F.** Risk factors and outcome of *C.Difficile* infection after hematopoietic stem cell transplantation. J Clin Med 2020; 16 (9) 3673.
48. Mina R, Joseph NS, Gay F, Kastrititis E, Petrucci MT, Kaufman JL, Montefusco V, Gavriatopoulou M, **Patriarca F,** …Dimopoulos MA. Clinical features and survival of multiple myeloma patients harboring t(14; 16) in the era of novel agents. Blood Cancer J 2020; 10 (4) 40.
49. Costa LJ, Iacobelli S, Pasquini MC, Modi R, Giaccone L, Blade J, Schonland S, Evangelista A, Perez-Simon JA, Hari P, Brown EE, Girald SA, **Patriarca F**,…Garthon G,Bruno B, Long-term survival of 1338 MM patients treated with tandem autologous vs autologous-allogeneic transplantation. Bone Marrow Transplantation 2020; 55(9):1810-1816
50. Castagna L, Busca A, Bramanti S, Raiola Anna M, Malagola M, Ciceri F, Arcese W, Vallisa D, **Patriarca F**, …Bonifazi F, Blaise D. Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. BMC Cancer 2020; 20 (1):1140
51. Olivieri A, Mancini G, Olivieri J, Marinelli Busilacchi E, Cimminiello M, Pascale SP, Nuccorini R, **Patriarca F**,…Ciceri F, Bonifazi F. Nilotinib in steroid-refractory cGVHD:prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). Bone Marrow Transplantation 2020; 55 (11):2077-2086
52. Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, **Patriarca F**,…Castagna L, Bruno B. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. Blood Adv 2020; 4 (16):3900-3912.
53. Farina L, Barretta F, Scarfo’ L, Bruno B, **Patriarca F**,…Corradini P, Montillo M. Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival and pathway inhibitors and allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2020; 26 (10):e256-e262.
54. Sperotto A, Candoni A, Petruzzellis G, Mullai R, **Patriarca F**, Tascini C, Fanin R. Screening procedure for Sars-Cov-2 infection combining triage, nasopharyngeal swab and serological test in allogeneic stem cell transplantation recipient undergoing outpatient posttransplant follow-up. J Med Vir 2021;93 (3):1244-1246.
55. **Patriarca F**, Sperotto A, Lorentino F, Oldani E, Mammoliti S, Isola M, Picardi A, Arcese W, Saporiti G, Sorasio R, Mordini N, avattoni I, Musso M, Borghero C, Micò C, Fanin R, Bruno B, Ciceri F, Bonifazi F. Donor luymphocyte infusions after allogeneic stem cell transplantation in acute leukemia: a survey from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Front Oncol 2020; 15;10:572918
56. Tiribelli M, Sperotto A, **Patriarca F**, Damiani D, Fanin R. Haploidentical transplant after failure of first allogeneic transplant: a long and winding road. Eur J Haematol 2021;106 (6):871-872
57. Zaiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso m, Gebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli T; **REACH Investigators**. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 2021; 385 (3):228-238.
58. Di Nora C, Sponga S, Ferrara V, **Patriarca F,** Fanin R, Nalli C, Lechiancole A, Vendramin I, Livi U. Emerging therapy in ligh-chain and acuired transthyretin-related amyloidosis: an Italian single-centre experience in heart transplantation. J Cardiovasc Med (Hagerstown) 2021; 22(4):261-267.
59. Castegna L, Dodero A, Patriarca F, Onida F, Olivieri A, Risso D, Giordano L, Majolino I, Bramanti S, Mariotti J, Sarina B, De Philippis C, Farina L, Carlo Stella C, Corradini P, Santoro A. Multicenter phase II study on haplodentical bone marrow transplantation using a reduced-intensity conditioning regimen and posttransplantation cyclophosphamide in patients with poor-prognosis lymphomas. Transplant Cell Ther 2021; 27 (4):328.e.1-328.e.6
60. Picardi A, Sacchi N, Miotti V, Lorentino F, Rambaldi A, Sessa M, Bruno B, Cerno M, Vago L,…**Patriarca F**, Pollichieni S, Mammoliti S, Miccichè S, Mangione I, Ciceri F, Bonifazi F. Allelic HLA matching and pair origin are favourable prognostic factors for unrelated hematopoietic stem cell transplantation in neoplastic hematological diseases: an Italian analysis by the Gruppo Italiano Trapianto di Cellule staminali e Terapie Cellulari, Italian Bone Matroow Registry and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. Transplant Cell Ther 2021; 27(5):406.e.1-406.e.11
61. Gay F, Guenther A, Offidani M, Engelhardt M, Salvini M, Montefusco V, **Patriarca F**,… Sonneveld P, Gramatzki M. Carfilzomib, bendamustine and dexamethasone in patients with advanced multiple myeloma.The EMN09 phase 1/2 study of the European Myeloma Network. Cancer 2021 Jun 28. Online ahead of print
62. Zaccaria GM, Bertamini L, Petrucci MT, Offidani M, Corradini P,…**Patriarca F,** benevolo G, Belotti A, Gaidano G, Nagler A, Hajek R, Spencer A, Sonneveld P, Musto P, Boccadoro M, Gay F. Development and validation of a simplified score to predict early relapse in newly diagnosed multiple myeloma in a pooled dataset of 2190 patients. Clin Cancer Res 2021; 27 (13):3695-3703.
63. Larocca A, Bonello F, Gaidano G, D’Agostino M, Offidani M,…Patriarca F, caravita di Toritto T, Corradini P, Tacchetti P, Boccadoro M, Bringhen S. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly,intermediate-fit patients in newly diagnosed multiple myeloma. Blood 2021;137 (22): 3027-3036.
64. D’Agostino M, Larocca A, Offidani M, Liberati AM, Gaidano G, Petrucci MT, Derudas D,…**Patriarca F,** Benevolo G, Giuliani N, Aitori G, guglieminelli T, Di Raimondo F, Corradino P, Musto P, Hajek R, Sonneveld P, Boccadoro M, Bringhen S. Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer J 2021;11 (4):73
65. Kroeger N, Sbianchi G, Sirait T, Wolschke C, Beelen D,…, **Patriarca F,** Di Renzo N, Yegin ZA, Hayden P, McLornan D, Yakoub-Agha I. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT. Leukemia 2021 May 22. Online ahead of print
66. Sperotto A, Candoni A, Gottardi M, Facchin G, Stella R, De Marchi R, Michelutti A, Cavallin M, Rosignoli C, **Patriarca F**, Fanin R. Cytomegalovirus prophylaxis vs pre-emptive strategy: different CD4+ e CD8+T cell reconstitution after allogeneic stem cell transplantation. Transplant Cell Ther 2021; 27(6):518.e1-518.e.4

Udine, 2022 June 27